The ATXN8OS Gene Spinocerebellar Ataxia Type 8 (SCA8) Autosomal Dominant Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE. This test is designed to identify mutations in the ATXN8OS gene, which are associated with the development of Spinocerebellar Ataxia Type 8, a progressive neurodegenerative disorder. SCA8 is characterized by a wide range of symptoms, including coordination and balance difficulties, speech and swallowing problems, and eye movement abnormalities. The condition is inherited in an autosomal dominant manner, meaning that a mutation in just one copy of the gene is sufficient to cause the disorder.
The test is critical for individuals with a family history of SCA8 or those exhibiting symptoms consistent with the condition, as it can provide a definitive diagnosis. Early identification of the disease can help in managing symptoms and planning for future care needs. The testing process involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of mutations in the ATXN8OS gene.
DNA Labs UAE offers this genetic test at a cost of 4400 AED. The facility is equipped with state-of-the-art technology and staffed by experienced professionals to ensure accurate and reliable results. Opting for this test at DNA Labs UAE not only aids in the diagnosis of SCA8 but also contributes to a better understanding of the genetic factors influencing the disorder, potentially guiding treatment options and family planning decisions.
The SYNE1 gene is associated with a condition known as Spinocerebellar Ataxia Type 8 (SCA8), which is a genetic disorder characterized by progressive problems with movement. This condition primarily affects the cerebellum, the part of the brain that controls coordination and balance. Symptoms of SCA8 may include uncoordinated movements, trouble walking, and issues with speech. It is an autosomal recessive disorder, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected by the condition.
To diagnose this condition, a specific genetic test is available at DNA Labs UAE, which focuses on identifying mutations in the SYNE1 gene that are responsible for SCA8. The test is crucial for confirming the diagnosis, understanding the risk of passing the condition to the next generation, and guiding management and treatment decisions. The cost of the SYNE1 gene Spinocerebellar Ataxia Type 8 Autosomal Recessive Genetic Test at DNA Labs UAE is 4400 AED. This test is a valuable resource for individuals with a family history of SCA8 or those exhibiting symptoms of the disorder, providing them with critical information about their genetic health.
The COQ8A gene spinocerebellar ataxia type 9 (SCAR9) autosomal recessive genetic test is a specialized diagnostic tool used to identify mutations in the COQ8A gene, which are linked to the development of SCAR9. Spinocerebellar ataxia type 9 is a rare genetic disorder characterized by progressive difficulties with coordination and movement, stemming from degeneration in specific areas of the brain, particularly the cerebellum. The autosomal recessive nature of the condition means that an individual must inherit two copies of the mutated gene, one from each parent, to be affected.
The test involves analyzing the individual's DNA, extracted from a blood sample, to look for specific genetic alterations in the COQ8A gene that are known to cause SCAR9. This genetic testing is crucial for early diagnosis, which can help in managing symptoms, planning for future healthcare needs, and providing information for family planning decisions.
In the United Arab Emirates, this genetic test is available at DNA Labs UAE, a leading provider of genetic testing services. The cost of the COQ8A gene spinocerebellar ataxia type 9 autosomal recessive genetic test at DNA Labs UAE is 4400 AED. This test is a significant resource for families and individuals at risk of SCAR9, offering them a chance to understand their genetic status and make informed decisions about their health and well-being.
The TDP1 Gene Spinocerebellar Ataxia with Axonal Neuropathy Autosomal Recessive Genetic Test is a specialized diagnostic assessment offered by DNA Labs UAE, designed to identify mutations in the TDP1 gene, which are implicated in the development of spinocerebellar ataxia with axonal neuropathy. This condition is a rare, inherited neurological disorder characterized by a progressive loss of muscle coordination (ataxia) and nerve damage (neuropathy), affecting movement and sensory functions. The test is crucial for individuals with a family history of the disorder or those exhibiting symptoms, providing essential information for accurate diagnosis and management. Priced at 4400 AED, this genetic test involves analyzing the patient's DNA to detect specific mutations in the TDP1 gene, helping in confirming the diagnosis and guiding treatment options, while also offering the possibility for family planning and genetic counseling for affected families.
The ANO10 gene is associated with a rare form of Spinocerebellar Ataxia, specifically Type 10 (SCA10), which is an autosomal recessive genetic disorder. This condition is characterized by progressive degeneration of the cerebellum, leading to coordination and balance difficulties, among other symptoms. Given the hereditary nature of SCA10, genetic testing is a crucial tool for diagnosis, family planning, and understanding the risk of transmission to offspring.
DNA Labs UAE offers a comprehensive genetic test targeting the ANO10 gene to identify mutations that cause Spinocerebellar Ataxia Type 10. This test is particularly important for individuals with a family history of SCA10 or those exhibiting symptoms suggestive of the condition. The genetic test is priced at 4400 AED and involves analyzing DNA samples to detect the presence of specific mutations in the ANO10 gene that are known to cause the disorder. By confirming a diagnosis through genetic testing, affected individuals can receive appropriate counseling, consider their options for management and treatment, and make informed decisions about family planning.
The TTBK2 gene plays a crucial role in the development of Spinocerebellar Ataxia Type 11 (SCA11), a condition characterized by progressive coordination problems due to cerebellar ataxia. This condition is inherited in an autosomal dominant manner, meaning only one copy of the altered gene in each cell is sufficient to cause the disorder. As a part of diagnostic measures, genetic testing for mutations in the TTBK2 gene can provide definitive confirmation of SCA11.
At DNA Labs UAE, individuals concerned about their genetic predisposition to SCA11 can undergo a specific genetic test targeting the TTBK2 gene. The cost of this test is set at 4400 AED. This test is crucial for individuals with a family history of SCA11, as it can help in early diagnosis, allowing for timely intervention and management strategies to slow the progression of symptoms. The testing process involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed for mutations in the TTBK2 gene.
The PPP2R2B gene is associated with Spinocerebellar Ataxia Type 12 (SCA12), a rare hereditary disorder characterized by progressive degeneration of the cerebellum, the part of the brain that is responsible for coordinating movement. This condition typically manifests as tremors, unsteady gait, and difficulty with fine motor tasks. SCA12 is an autosomal dominant condition, meaning that an individual only needs a single copy of the altered gene from one parent to be affected.
To diagnose this condition, a genetic test targeting the PPP2R2B gene can be conducted. This test looks for specific mutations in the gene that are known to cause SCA12. Identifying these mutations can confirm a diagnosis, help assess the risk of passing the condition to offspring, and aid in the management and treatment of symptoms.
In the United Arab Emirates, DNA Labs UAE offers this specific genetic test. The cost of the test is 4400 AED. DNA Labs UAE is equipped with state-of-the-art technology to provide accurate and reliable genetic testing services. By opting for this test, individuals who have a family history of SCA12 or exhibit symptoms associated with the condition can gain valuable insights into their genetic makeup, enabling informed decisions regarding their health and future.
The "WWOX Gene Spinocerebellar Ataxia Type 12 Autosomal Recessive Genetic Test" is a specialized diagnostic procedure designed to identify mutations in the WWOX gene, which have been linked to Spinocerebellar Ataxia Type 12 (SCA12), an autosomal recessive neurodegenerative disorder. This condition is characterized by progressive coordination problems, difficulty with speech, and tremors due to cerebellar atrophy. The test aims to provide crucial genetic information for affected individuals and their families, facilitating early diagnosis and management of the condition.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test employs advanced genomic technologies to ensure accurate and reliable results. The cost of the test is set at 4400 AED, reflecting the comprehensive analysis and expertise required to interpret the genetic data accurately. This test is pivotal for at-risk families, offering insights into genetic predispositions and enabling informed decisions regarding health management and potential treatments.
The KCNC3 gene is associated with a condition known as Spinocerebellar Ataxia Type 13 (SCA13), which is a type of hereditary ataxia. SCA13 is characterized by a progressive degeneration of the cerebellum, the part of the brain that is responsible for coordinating movement. This condition leads to symptoms such as uncoordinated movement, poor balance, and difficulty with speech. SCA13 is inherited in an autosomal dominant manner, meaning that an individual only needs a single copy of the altered gene from one parent to be affected.
A genetic test is available to identify mutations in the KCNC3 gene, which can confirm a diagnosis of SCA13. This test is crucial for individuals with a family history of the condition or those exhibiting symptoms, as it can provide a definitive diagnosis and help guide management and treatment options. Additionally, it can offer information for family planning.
In the UAE, this specific genetic test can be conducted at DNA Labs, a facility known for its comprehensive genetic testing services. The cost of the KCNC3 gene test for Spinocerebellar Ataxia Type 13 at DNA Labs UAE is 4400 AED. This test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory to detect mutations in the KCNC3 gene. The results of this test can provide individuals and families with essential information regarding the diagnosis, prognosis, and inheritance pattern of SCA13, enabling them to make informed decisions about their health and future.
The PRKCG Gene Spinocerebellar Ataxia Type 14 Autosomal Dominant Genetic Test is a specialized diagnostic procedure designed to identify mutations in the PRKCG gene, which are known to cause Spinocerebellar Ataxia Type 14 (SCA14). SCA14 is a form of spinocerebellar ataxia, a neurodegenerative disorder characterized by progressive problems with movement, coordination, and balance, due to degeneration of the cerebellum and its connections. It is inherited in an autosomal dominant manner, meaning a mutation in just one of the two copies of the gene in each cell is sufficient to cause the disorder.
This test is particularly crucial for individuals with a family history of SCA14, displaying symptoms of the condition, or couples planning to have children and wanting to assess the risk of passing the condition onto their offspring. By analyzing the DNA to detect mutations in the PRKCG gene, this test can confirm a diagnosis of SCA14, assist in the management and treatment of the condition, and provide essential information for genetic counseling.
The test is offered by DNA Labs UAE, a facility known for its state-of-the-art genetic testing services. The cost of the PRKCG Gene Spinocerebellar Ataxia Type 14 Autosomal Dominant Genetic Test is 4400 AED. Given the complexity of the condition and the implications of the test results, individuals are often advised to undergo genetic counseling before and after the test to fully understand the potential outcomes and their impact.
